LYEL
Lyell Immunopharma, Inc.
There isn't enough reported data to score LYEL yet.
LYEL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
LYEL's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LYEL PE Valuation
LYEL has no meaningful PE right now: it lost money over the past year.
LYEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect LYEL's revenue to grow, with its earnings and profitability holding steady.
LYEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.32 | +$10.70 |
| Q2 2026 | -$12.59 | +$11.70 |
| Q1 2026 | -$13.56 | +$11.44 |
| Q4 2025 | -$16.06 | +$10.14 |
| Q3 2025 | -$23.02 | -$7.22 |
| Q2 2025 | -$24.29 | -$7.89 |
| Q1 2025 | -$25.00 | -$7.00 |
| Q4 2024 | -$26.20 | -$7.60 |
LYEL is still losing money, but far less than before: $12.32 per share over the past year, against $26.20 at its worst in late 2024.
LYEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3K | -80% |
| Q2 2026 | $4K | -50% |
| Q1 2026 | $2K | -71% |
| Q4 2025 | $6K | -45% |
| Q3 2025 | $15K | -56% |
| Q2 2025 | $8K | -38% |
| Q1 2025 | $7K | +133% |
| Q4 2024 | $11K | -15% |
LYEL's revenue has slid since its 2022 peak: $3,000 last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1609833% | -1361480 points |
| Q2 2026 | -1183425% | -594175 points |
| Q1 2026 | -2213050% | -1393521 points |
| Q4 2025 | -2127400% | -298791 points |
| Q3 2025 | -248353% | -99809 points |
| Q2 2025 | -589250% | -192881 points |
| Q1 2025 | -819529% | +1032971 points |
| Q4 2024 | -1828609% | -1370855 points |
LYEL's operating margin was −1609833% last quarter, down 1361480 points from the same quarter a year ago.
LYEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.6M | -$6M |
| Q2 2026 | -$34.2M | +$448K |
| Q1 2026 | -$38.6M | +$16.4M |
| Q4 2025 | -$32.6M | +$14.7M |
| Q3 2025 | -$28.6M | +$6.5M |
| Q2 2025 | -$34.6M | +$3.8M |
| Q1 2025 | -$55M | -$12.9M |
| Q4 2024 | -$47.3M | -$6.6M |
LYEL has burned cash in almost every quarter: −$140M over the past year, against −$166M the year before.
LYEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +1.1M shares |
| 1 year | +65% | +9.6M shares |
| 3 years | +95% | +11.9M shares |
| 5 years | +105% | +12.5M shares |
LYEL has 24M diluted shares, up 65% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $11.8M |
LYEL Net Leverage
LYEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LYEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 65.6 | Neutral |
LYEL's weekly RSI is 55 (neutral) and its Stochastic is 66 (neutral).
LYEL PE vs Healthcare Sector
LYEL has no meaningful PE right now: it lost money over the past year.
LYEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 44% above |
| 20 week MA | $12.5 | 25% above |
| 50 week MA | $18.3 | 14% below |
| 100 week MA | $15.3 | 2.2% above |
| 200 week MA | $28.4 | 45% below |
LYEL's trend is mixed: it's above three of its five weekly moving averages, and 45% below its 200-week average.
LYEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $324.0 | $164.2 | -49% |
| 2022 | $164.2 | $61.0 | -63% |
| 2023 | $61.0 | $38.8 | -36% |
| 2024 | $38.8 | $13.0 | -66% |
| 2025 | $13.0 | $35.1 | +170% |
| 2026 YTD | $35.1 | $15.6 | -55% |
LYEL's yearly returns have swung widely, from +170% in 2025 to −66% in 2024. It's down 55% so far in 2026.